罗氟司特治疗慢性阻塞性肺疾病的临床研究进展

Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

慢性阻塞性肺疾病(COPD)是一种常见疾病,其特征通常是持续性、进行性的气流受限,气道的慢性炎性反应增强,可能出现急性加重及并发症。罗氟司特是经欧盟和美国食品药品管理局批准,在COPD治疗中惟一可通过口服给药的磷酸二酯酶-4抑制剂,具有强大的抗炎作用和中等程度的支气管扩张作用,可有效改善肺功能,显著降低中/重度COPD患者的恶化率,预防急性加重,在重度急性加重COPD患者治疗中具有广阔的应用前景。本文综述罗氟司特在COPD治疗中的临床研究进展。

Chronic obstructive pulmonary disease(COPD) is a common disease characterized by persistent and progressive airflow limitation, which increases chronic inflammatory response in the airway with acute exacerbation and complications. Roflumilast is the only phosphodiesterase-4 inhibitor that can be oral administration for the treatment of COPD approved by the EU and FDA. Roflumilast has a strong anti-inflammatory effect and moderate bronchial dilatation, which can effectively improve lung function, and significantly reduce the deterioration in moderate and severe COPD patients, to prevent from acute exacerbations. This review summarizes the advances of roflumilast in the clinical treatment of COPD.